BeOne Medicines AG (ONC)
NASDAQ: ONC · Real-Time Price · USD
340.61
-0.03 (-0.01%)
At close: Nov 28, 2025, 1:00 PM EST
337.96
-2.65 (-0.78%)
After-hours: Nov 28, 2025, 4:59 PM EST
BeOne Medicines AG Revenue
BeOne Medicines AG had revenue of 10.28B CNY in the quarter ending September 30, 2025, with 46.28% growth. This brings the company's revenue in the last twelve months to 35.59B, up 53.47% year-over-year. In the year 2024, BeOne Medicines AG had annual revenue of 27.81B with 59.51% growth.
Revenue (ttm)
35.59B CNY
Revenue Growth
+53.47%
P/S Ratio
7.35
Revenue / Employee
3,235,022 CNY
Employees
11,000
Market Cap
37.69B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.81B | 10.38B | 59.51% |
| Dec 31, 2023 | 17.43B | 7.67B | 78.53% |
| Dec 31, 2022 | 9.77B | 2.29B | 30.69% |
| Dec 31, 2021 | 7.47B | 5.46B | 270.56% |
| Dec 31, 2020 | 2.02B | -965.08M | -32.37% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ONC News
- 2 days ago - Artisan International Small-Mid Fund Q3 2025 Performance Review - Seeking Alpha
- 2 days ago - U.S. FDA Grants Priority Review to Sonrotoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Business Wire
- 8 days ago - BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025 - Business Wire
- 11 days ago - BeOne Medicines AG (ONC) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 11 days ago - Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma - Business Wire
- 17 days ago - BeOne Medicines AG (ONC) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript - Seeking Alpha
- 22 days ago - BeOne Medicines AG (ONC) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates - Business Wire